Spotlighting the Clinical Profile & Positioning of IKS014 to Contextualize ADC Sequencing - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Spotlighting the Clinical Profile & Positioning of IKS014 to Contextualize ADC Sequencing

3:00 pm - Tuesday 13th October 2026

Understanding the importance of ADC clinical positioning in previously treated patients against current therapies
Highlighting the updated Phase I clinical profile of IKS014 for patients with advanced HER2+ solid tumors
Addressing the concept of ADC sequencing in future treatment paradigms

Speakers:

Jutta Deckert

Jutta Deckert

Vice President - Research & Development

Iksuda Therapeutics